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ased on WHO / National guideline criteria’s. Like ﬁrst line
RT combinations for initiating treatment and second line
RT combinations for treating ﬁrst line treatment failure
onditions. There are many combinations of ﬁrst line drugs
nd it is important to deﬁne are all these ﬁrst line regimens
qually effective in real clinical set ups.
Methods: We conducted a retrospective chart review
f the outcome of different ART regimens among 300
IV- infected patients whose CD4 count was less than
00 cells/mm3 on initiation of ART and has regular fol-
ow up at Gondar University Hospital in Gondar, Ethiopia
etween September 2008 and March 2009, who received
tandard ﬁrst line combination ART regimens. Group 1
N = 100) include those treated with AZT, 3TC, EFV/NVP
ombinations, Group 2 (N = 100) include those treated with
4T, 3TC, EFV/NVP combinations and Group 3 (N = 100)
nclude those treated with TDF, 3TC, EFV/NVP combina-
ions.
Results: There were no difference between Group 1,
and 3 with regard to: IRIS [Ten (10%), Thirteen (13%)
nd Eleven (11%), P = ns] respectively; new opportunistic
nfections [Four (4%), Seven (7%), and Three (3%), P = ns]
espectively; average CD4 increment by 30% [Eighty (80%),
eventy six (76%), and Eighty three (83%), P = ns] respec-
ively and death [Six (6%), Five (5%), and Four (4%), P = ns]
espectively. However, adverse drug side effect occurs more
requently in Group 1 and 2 than in Group 3 [Eighteen (18%)
nd Twenty (20%) versus Three (3%), P = 0.03] respectively,
hich more frequently resulted poor adherence in Group
and 2 than Group 3 [Seventeen (17%) and Sixteen (16%)
ersus Three (3%), P = 0.05] respectively.
Conclusion: This manuscript shows that in a retrospective
eview of HIV patients who are in different Antiretroviral
rug combination regimens attending follow ups at GUH,
he clinical and immunological responses for the different
RT regimens are similar and comparable however it depicts
ifferences in areas of drug side effects and adherence prob-
ems. Therefore different ﬁrst line ART drug combinations
election in resource poor countries can be guided by drugs
ide effect and adherence issues.
oi:10.1016/j.ijid.2010.02.2025
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Background: Non nucleoside reverse transcriptase
nhibitors (NNRTI) based regimens are widely recommended
s 1st line HAART and they are preferred in resource
onstrained settings due to high efﬁcacy and low cost. Few
tudies compare effectiveness of efavirenz (EFV) and nevi-
apine (NVP) in large, prospective cohorts with extended
ollow up (f/u). Objective: To determine the effectiveness,
ate of discontinuation or change, toxicity and mortality
o
d
i
bternational Congress on Infectious Diseases (ICID) Abstracts
f patients with EFV versus NVP based regimens as initial
AART in a nation wide cohort.
Methods: Prospective, open label, f/u of patients
nrolled in the Chilean AIDS Cohort (ChiAC) from October
001 to March 2008. All subjects receiving at least one dose
f EFV or NVP were included. Primary outcomes were sur-
ival, maintenance of initial HAART, reason for change of
NRTI, viral suppression and immune recovery.
Results: Of 5120 patients initiating ﬁrst HAART in ChiAC,
187 started a NNRTI based regimen (plus 2 NRTIs); 3107
74.2%) with EFV and 1080 (25.8%) with NVP. Median f/u
as 2.7 years. At baseline the NVP group had a signiﬁcantly
ess advanced stage (CDC classiﬁcation) and higher median
D4 count (151 vs 86 cell/mm3 in EFV, p < 0.001), but similar
iral load (VL) compared to the EFV group. Rate of change
r discontinuation was signiﬁcantly lower for EFV (12.8% vs
2.3%, p < 0.001), due to fewer adherence problems or toxi-
ity. Timing for change was similar in both arms (median 950
s 1008 days for EFV and NVP respectively). There were no
tatistical differences in viral suppression rate (<80 cps/mL)
t any time: 67.2, 74.9, 74.4, 65.1, 59.8% vs 63.6, 74.3,
2.7, 61.7, 59.4% at 6, 12, 24, 36 and 48 months for EFV
nd NVP respectively. At 12 months of f/u median CD4 cell
ount was similar for groups (242 for EFV and 250/mm3 for
VP). Mortality for the total period was 2.89 and 2.85 per
00pts-year for EFV and NVP respectively (p =NS).
Conclusion: Efavirenz based HAART regimens were asso-
iated with similar viral and immune outcomes as Nevirapine
ased regimens, despite more severe disease at baseline in
he EFV group. Discontinuation of NVP was more frequent,
ainly due to toxicity and lower adherence, but not to viral
ailure.
oi:10.1016/j.ijid.2010.02.2026
5.003
he economic impact of introducing HIV/AIDS guide-
ine into Colombian National Drug Formulary. Cost-
ffectiveness analysis
.V. Lemos Luengas ∗, B.C. Castan˜eda, E. Quevedo, C.
astillo, L.R. Lemos
Fundacion para el Desarrollo y Apoyo en Salud Internacional
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Background: Colombia has >165000 people infected
ith human immunodeﬁciency virus (HIV). In 2009, the
orld Health Organization (WHO) estimated only 40% had
ntiretroviral therapy coverage. Colombia’s AIDS treatments
uidelines became available in 2006 and are currently being
sed by physicians in their daily practice. However, these
uidelines have not yet been evaluated with respect to their
elative costs and effectiveness.
Methods: A Markov model was developed using TreeAge
Pro-2009 and clinical experts. Success probabilities were
erived from published randomized controlled trials. Drug
osts were obtained from the 2009 Drug Price Guideline from
ogotá and the ISS 2008 Manual. Hospitalization costs were
btained from theWest Kennedy Hospital, Bogotá 2008/2009
atabase, adjusted to 2008. One-way and two-way sensitiv-
ty analyses were performed to test the model’s robustness
y varying clinical success rates and costs of antiretrovirals.
